The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center

Table 1 The clinical features of CLL/SLL patients

Case	Age/sex	Time (months)	Scr (μmol/L)	UTP (g/24 h)	MIg	Cryo	C3 (g/L)	C4 (g/L)	ER-IO	Treatment	F. time (months)	Renal outcome	CLL/SLL
1	67/M	2	118	10.35	IgMλ	Trace	0.57↓	0.12	LN	CYC, CsA	56	Not recovery	Stable
2	66/M	0	616	0.80	Negative	Trace	0.63	0.26	LN, BM	Supportive	52	ESRD (never recovered)	Stable
3	58/F	0	95	1.15	IgGκ	Negative	0.92	0.21	BM	COP, Rituximab Ibrutinib	32	Completely recovery	Improved
4	58/F	0	174	0.48	IgMκ	Negative	0.48↓	0.05↓	LN,BM	RFC	31	Completely recovery	Stable
5	66/F	60	570	0.87	Negative	NA	0.72	0.34	LN, Spleen BM	CHOP, Ibrutinib	15	Partial recovery	Stable
6	62/M	36	118	4.27	IgGκ	IgGκ	0.57↓	0.09↓	LN,BM	COP, Ibrutinib	8	Completely recovery	Stable
7	68/F	18	456	2.17	Negative	NA	0.81	0.16	LN,	Prednisone	6	Partial recovery	Improved
8	59/F	0	377	0.59	IgMκ	Type II	0.46↓	0.02↓	LN,BM	PE for TMA	33	Partial recovery	Progressed
9	73/M	3	161	1.44	Negative	Negative	0.76	0.20	BM	Supportive	2	Not recovery	Stable
10	67/M	0	221	12.8	IgMκ	IgMκ	0.244↓	0.06↓	LN,BM	Ibrutinib	1	Partial recovery	Stable

Notes: Time: time from diagnosis of CLL/SLL to renal biopsy; Scr: serum creatinine at renal biopsy
Abbreviations: UTP urine total protein, MIg monoclonal immunoglobulin determined by serum/urine immunofixation electrophoresis; Cryo cryoglobulinemia, ER-IO extra-renal involved organs, F.time follow up time, LN lymph node, BM bone marrow, CYC cyclophosphamide, CsA cyclosporine, ESRD end stage renal disease, COP cyclophosphamide, vincristine, and prednisone, RFC rituximab, fludarabine and cyclophosphamide, CHOP cyclophosphamide, doxorubicin, vincristine and prednisone, PE plasma exchange, TMA thrombotic microangiopathy

ISSN: 1746-1596